The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.
Gilles Salles MD, PhD
Advertisement
Articles by Gilles Salles MD, PhD
Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.
Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.
Advertisement
Latest Updated Articles
Dr. Salles on Frontline Management of Follicular LymphomaPublished: March 1st 2017 | Updated:
Dr. Salles on New Agents Being Investigated in Follicular LymphomaPublished: April 11th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5